Straits Times Index
3,280.10 -7.65 (-0.23%) S&P 500
5,099.96 +51.54 (+1.02%) Dow
38,239.66 +153.86 (+0.40%) Nasdaq
15,927.90 +316.14 (+2.03%) Bitcoin USD
63,589.48 +597.56 (+0.95%) CMC Crypto 200
1,390.35 -6.19 (-0.44%)
Heart Test Laboratories, Inc. (HSCS)
After hours:
| Previous close | 0.0999 |
| Open | 0.0969 |
| Bid | 0.0000 x 0 |
| Ask | 1.2500 x 100 |
| Day's range | 0.0936 - 0.1016 |
| 52-week range | 0.0910 - 1.3200 |
| Volume | |
| Avg. volume | 1,906,242 |
| Market cap | 6.386M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3500 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.68 |
GlobeNewswireHeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart diseaseSouthlake, Texas, April 24, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that its European P
- GlobeNewswire
HeartSciences to Present at the LD Micro Invitational XIV Conference
Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel Ne
- GlobeNewswire
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be RecommendedSouthlake, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the podium presentation of a study utilizing its MyoVi
